Format: Symposium

1-6 of 7 Activities
Title
Availability
Format
Credits
Launch Date
Buttons

The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

In this CE Concepts recorded symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans that reflect current clinical standards and support individualized, longitudinal management.

1.5
09/15/2025

Renie Moss

Renie Moss

Carlos Romo, MD

Carlos Romo, MD

Miriam Bornhorst, MD

Miriam Bornhorst, MD

Angela Hirbe, MD, PhD

Angela Hirbe, MD, PhD

Moderator

Live
Symposium
1
11/21/2025 at 10:15 PM EST

Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN

This CE Concepts live symposium will address these critical gaps by equipping neuro-oncologists, neurosurgeons, radiation oncologists, medical oncologists, advanced practitioners, and nurses with strategies for early recognition of NF1-associated tumors, effective integration of MEK inhibitors, and development of evidence-based, interprofessional care plans that support individualized, longitudinal management.

1
11/21/2025 at 10:15 PM EST

Darren Hargrave, MB.Chb (Hons), MD, MRCP, FRCPCH

Darren Hargrave, MB.Chb (Hons), MD, MRCP, FRCPCH

Live
Symposium
1.5
10/09/2025 at 11:45 AM EDT

The MEKtrix: Advancing Neurofibromatosis Type 1 Care Across the Lifespan

In this CE Concepts live symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans for patients with NF1 that reflect current clinical standards and support individualized, longitudinal management.

1.5
10/09/2025 at 11:45 AM EDT

Kaleb H. Yohay, MD

Kaleb H. Yohay, MD

Renie Moss

Renie Moss

Lionel Chow, MD, PhD

Lionel Chow, MD, PhD

Rebecca Brown, MD, PhD

Rebecca Brown, MD, PhD

Moderator

Livestream: The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

In this CE Concepts livestream symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans that reflect current clinical standards and support individualized, longitudinal management.

1.5
09/14/2025 at 3:30 PM EDT

Renie Moss

Renie Moss

Carlos Romo, MD

Carlos Romo, MD

Miriam Bornhorst, MD

Miriam Bornhorst, MD

Angela Hirbe, MD, PhD

Angela Hirbe, MD, PhD

Moderator

The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

In this CE Concepts live symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans that reflect current clinical standards and support individualized, longitudinal management.

1.5
09/14/2025 at 3:30 PM EDT

Renie Moss

Renie Moss

Carlos Romo, MD

Carlos Romo, MD

Miriam Bornhorst, MD

Miriam Bornhorst, MD

Angela Hirbe, MD, PhD

Angela Hirbe, MD, PhD

Moderator

Live
Livestream Symposium, Symposium
1
09/27/2025 at 12:00 PM EDT

Livestream: MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management

In this CEC Oncology livestream, case-based symposium, expert faculty will discuss key characteristics of clinical presentation and disease advancement over a lifespan; review patient and caregiver education needs on the integration of MEK inhibitors in the management of NF1-associated PNs; and explore the role of nurses in comprehensive care plans, including disease monitoring, treatment personalization, toxicity management, and transitioning care of patients with NF1 across their lifespan.

1
09/27/2025 at 12:00 PM EDT

Renie Moss

Renie Moss

Sanita Burgic, MSN, APRN, AGNP-C

Sanita Burgic, MSN, APRN, AGNP-C

AeRang Kim, MD, PhD

AeRang Kim, MD, PhD

Amy Armstrong, MD

Amy Armstrong, MD